Soft Tissue and Orthopedic Surgery

Below, please find links to all of the clinical trials involving soft tissue or orthopedic surgery. The studies include a multitude of information, including (but not limited to) the study’s purpose, benefits for participating, and financial incentive information. If you have any questions, please contact the individual outlined at the end of each trial summary.

Please visit the Surgery service webpage at the Veterinary Medical Teaching Hospital (VMTH) if you would like to learn more about the amazing things that our surgeons can do for you and your animal.

Dogs

Bloat (Gastric Dilation and Volvulus): Investigating a Preventative Surgical Technique

Title: A Radiologic Percutaneous Gastropexy Technique in Dogs

Purpose of Study: Commonly referred to as "bloat", gastric dilation and volvulus (GDV) is a life-threatening syndrome that occurs when a dog’s stomach becomes distended with air and/or food and rotates. The rotation of the stomach restricts outflow of stomach contents and more importantly causes a reduction in the blood flow to the stomach wall causing death of the tissues. This disease is considered universally fatal if left untreated. Additionally, if the stomach wall is devitalized from lack of blood flow, significant post-operative care may be necessary making this surgery cost prohibitive for many owners and resulting in humane euthanasia. Performing a gastropexy has been shown to virtually eliminate the possibility of a subsequent torsion. Therefore, the goal of this study is to the evaluate if a minimally invasive gastropexy (using a T-fastener) is a viable method of performing gastropexies in dogs predisposed to developing GDV.

Participation Requirements: Dog breeds that are predisposed to gastric dilation and volvulus (GDV)

Initial Evaluation for Participation: Contact Dr. Culp for details at wculp@ucdavis.edu or (530) 752-1393.

Procedures: Your dog will undergo non-invasive ultrasound evaluations before the procedure as well as 2 days and then 2 months after the procedure. During the procedure, your dog will be anesthetized and a T-fastener gastropexy will be performed utilizing radiography/fluoroscopy (real time “x-rays”).

Benefits: All costs associated with the study will be paid by the sponsor/department with the exception of the anesthesia (average of $300-500) and any complications that may occur as part of that procedure. For more information about possible costs, please contact the investigator.

We cannot promise any benefits to your dog or other animals from your taking part in this clinical trial; however, direct benefits of enrolling in this study include financial support for the ultrasound and procedure. We hope that the data acquired in this study will allow us to advance the treatment of our canine patients.

Owner Responsibilities: You are responsible for cost of anesthesia (average of $300-500) and any complications that may occur as part of that procedure. Dogs enrolled in this study will need an ultrasound performed before the procedure as well as 2 days post-procedure and 2 months post-procedure. If you allow your dog to participate in this study, you will need to bring your dog in for an ultrasonographic evaluation 2 days post-procedure and 2 months post-procedure.

Contact: Contact Dr. Culp for details at wculp@ucdavis.edu or (530) 752-1393.

Printable Flyer (PDF)

Hiatal Hernia / Brachycephalic Obstructor Syndrome: Assessing a Surgical Treatment

Title: Effect of Surgical Treatment of Brachycephalic Obstructor Syndrome on the Lower Esophageal Area of Brachycephalic Dogs with Evidence of Hiatal Herniation and Gastroesophageal Reflux

Purpose of Study: We believe that brachycephalic dogs have a tendency to develop hiatal herniation (HH) with greater frequency than non-brachycephalic dogs. Dogs with relative obstruction of the upper airways may generate a decreased pressure in their chest during inspiration (breathing in) that results in the upper part of the stomach being sucked into the chest (HH). This can lead to clinical signs including regurgitation, esophageal stricture formation and aspiration pneumonia if severe. We hypothesize that, if the upper airway obstruction in these dogs can be alleviated, improvement in their respiratory compromise might be seen as well as a reduction in the severity of their HH.

Participation Requirements:

  • Brachycephalic breed (dogs with broad short skulls)
  • No evidence of other upper airway obstructive pathology (especially tracheal collapse and hypoplastic trachea)
  • No previous brachycephalic surgery
  • Evidence of hiatal herniation on fluoroscopic imaging (performed pre-operatively)

Initial Evaluation for Participation: Initial evaluation and discussion for entry into the study can be arranged by making an appointment with our Internal Medicine or Soft Tissue Surgery or by contacting Dr. Phil Mayhew directly (contact information below).

Procedures: Both visits outlined below require hospitalization for 2-4 days at the VMTH.

  • First visit:
    • Day 1: You will be asked to fill out a questionnaire about your dog’s clinical signs. We will give your dog a local anesthetic, place a small catheter down your dogs nose, and give your dog a small amount of water to swallow, so we can trace the pressure profile of your dog’s esophagus (known as high-resolution manometry or HRM study). We will then perform a barium esophagram, which involves imaging of your dog using a fluoroscope (moving x-ray machine) after he/she swallows water and food boluses. Finally, we will place a small pH-monitoring probe in you dog’s nose that will remain in place for no longer than 24-hours for continuous monitoring of the esophageal pH and will be removed prior to surgery the following day.
    • Day 2: Your dog will be prepared for surgery and given general anesthesia. Prior to surgery, we will take measurements of your dog’s lower esophageal area (impedance planimetry or Endoflip), which involves inflation of a very low-pressure balloon within the lower esophagus, and perform an upper gastrointestinal endoscopic study immediately before upper airway surgery.
  • 30 – 60 days post-surgery visit: You will need to bring your dog in for another visit between 30 and 60 days after surgery. During this visit, we need to repeat the questionnaire and the procedures outlined above to gauge the response to surgery.

Benefits: The trial will pay for all of the diagnostic tests associated with the study, including costs associated with the HRM and esophagram studies, Endoflip measurements, pH impedance studies, endosocopic studies, biopsy procedures, pathology fees as well as the hospitalization and anesthesia fees associated with the second visit to the hospital at 30-60 days post-operatively. The owner will have to cover the surgical procedure, hospitalization and any possible complications associated with the surgical procedure and recovery during the first visit.

We cannot promise any benefits to your dog or other animals from your taking part in this clinical trial; however, possible benefits include a better understanding of your dogs presence or absence of hiatal herniation which may aid in longer-term management of this component of his or her clinical signs. Results from this study may influence treatment of other dogs with similar conditions going forward.

Owner Responsibilities: If you allow your dog to participate in this study, you will be responsible for bringing the dog to the VMTH for the study-related visits for the duration of the time stipulated and for providing the clinical information stipulated.

Contact:

  • Please call (530) 752-1393 to make an appointment with Soft Tissue Surgery or Internal Medicine for Dr. Phil Mayhew's study
  • Email Dr. Phil Mayhew directly at philmayhew@gmail.com
Imaging: Using New Imaging Techniques During Surgery

Title: Intraoperative Near-Infrared Fluorescent Imaging

Purpose of Study: Near-infrared fluorescent imaging utilizes light just out of the visual spectrum to generate additional imaging information in the treatment of a wide variety of diseases.  The near infrared light is generated by a special contrast agent (Indocyanine Green) that is injected into the patient.  When a near-infrared light source is used to illuminate the surgical site, any tissue in which this contrast agent is located will glow, aiding the surgeon in identifying the location or extent of disease.  Based on early experiments in rodents and human clinical trials, this very sensitive tool has the potential to improve surgical decision-making and improve overall treatment for a wide variety of diseases including various tumors, sentinel lymph node identification, assessing viability of skin flaps, identification of liver shunts, identification of urinary tract obstruction or trauma, identification of bilary tract obstruction or trauma, assessment of gastrointestinal perfusion, and treatment of difficult wounds.  The purpose of this study is to evaluate the efficacy of this imaging modality in veterinary patients presenting with natural disease processes.

Participation Requirements: Dogs scheduled for surgery.

Initial Evaluation for Participation: Evaluation by Dr. Michele Steffey on the Soft Tissue Surgery Service.

Procedures: Indocyanine Green will be administered, either subcutaneously or intravenously, at a dose and timing considered to be optimal by your attending veterinarian.

Benefits: There may or may not be a specific benefit to your dog by participating in this study.  Use of Indocyanine Green may or may not aid in the intraoperative decision-making by the veterinary surgeon.

Owner Responsibilities: If an allergic reaction should occur, immediate costs of treatment (diphenhydramine, support of blood pressure) will be covered by the study; however, the owner will be responsible for any treatment costs for prolonged or severe complications.

Contact: Call the scheduling coordinators in Soft Tissue Surgery at (530) 752-1393 for Dr. Steffey's study.

Intrahepatic Portosystemic Shunts: Assessing a New Treatment Technique

Title: Assessment of Outcome in Dogs Undergoing Percutaneous Transvenous Coil Embolization to Treat Intrahepatic Portosystemic Shunts

Purpose of Study: The purposes of this project are to:

  1. Evaluate serum bile acid concentrations and hepatic biochemical functional parameters (BUN, albumin, cholesterol, glucose, and bilirubin) in dogs with intrahepatic portosystemic shunts both pre- and post-treatment to objectively evaluate each patient for improvement in hepatic function.
  2. Assess the improvement in the clinical signs of dogs with IHPSS after the performance of PTCE.
  3. To perform imaging studies pre- and post-PTCE that provide objective assessment of outcome associated with the PTCE procedure.

Participation Requirements: Dogs with intrahepatic portosystemic shunts

Initial Evaluation for Participation: Contact Dr. Culp for details at wculp@ucdavis.edu or (530) 752-1393.

Procedures: Dogs with a diagnosis of intrahepatic portosystemic shunts (IHPSS) will be enrolled in the study. The dog will undergo percutanous transvenous coil embolization (PTCE) to treat his/her IHPSS. Prior to and after this procedure, diagnostics including bloodwork, nuclear scintigraphy, abdominal ultrasound and computed tomography (CT) scan will be performed and compared.

Benefits: Enrolling a dog in this study results in a significant financial incentive towards diagnostics that would be recommended for the dog whether or not he/she is enrolled in the study. This benefit includes payment of the preoperative CT scan and the postoperative bloodwork (1 chemistry panel at 3 months postoperative), ultrasound (1 at 3 months postoperative), nuclear scintigraphy scan (1 at 3 months postoperative) and CT scan (1 at 3 months postoperative).

Owner Responsibilities: Return the patient 3 months after treatment for further assessment.

Contact: Contact Dr. Culp for details at wculp@ucdavis.edu or (530) 752-1393.

Large Bowel Disease: Evaluating a New Diagnostic Tool

Title: Evaluation of CT as a diagnostic tool for large bowel disease in dogs

Purpose of Study: We are evaluating the benefits of a novel CT protocol for large bowel disease. Surgical planning for conditions of the large bowel can be difficult as there are many ways to surgically approach lesions of the large bowel. Appropriate surgical planning plays a large role in the success of the procedure. While existing imaging methods provide some information about the lesion, there are sometimes major limitations to the information provided. Three-dimensional imaging, such as CT, is likely to improve our understanding of the disease and, our surgical planning in cases of mass lesions.

Participation Requirements:

  • Dogs experiencing clinical signs of large bowel disease (colon or rectum)
  • As the owner, you have elected to have a colonoscopy and biopsies performed under general anesthesia for diagnosis of the underlying disease

Initial Evaluation for Participation: Evaluation by the UCDavis VMTH Internal Medicine Service

Procedures: If you agree to participate, your dog will be anesthetized according to standard of care recommended by the Anesthesia Service. Prior to your dog’s scheduled colonoscopy, your dog will go to CT for the imaging scan using a new technique. He/she will then proceed for his/her colonoscopy/biopsy procedure as planned.

Benefits: There is no charge for you to allow your dog to participate in this clinical trial as all costs associated with the study, including the CT scan and additional anesthesia time needed to perform the CT imaging will be paid by the sponsor/department. You will additionally receive an additional $150 subsidy on your bill toward the cost of the colonoscopy procedure.

We cannot promise any benefits to your dog or other animals from your taking part in this clinical trial; however, possible benefits include improved methods of diagnosis of large bowel disease or improved surgical planning for focal large bowel problems.

Owner Responsibilities: If you allow your dog to participate in this study, you will be responsible for bringing your dog to the U.C. Davis Veterinary Medical Teaching Hospital (VMTH) for his/her scheduled colonoscopy procedure and for covering the standard costs of the colonoscopy/biopsy/regular medical care as part of the diagnosis of your dog’s disease.

Contact: If you are interested in participating in this clinical trial, please schedule an appointment with the UCD VMTH Internal Medicine Service at 530-752-1393. For specific procedure questions, have your veterinarian contact Dr. Michele Steffey at 530-752-1393 and following the prompts for Surgery.

Printable Flyer (PDF)

Anal Sac Gland Carcinoma: Using CT Lymphography to Assess Lymphatic Center

Title: Assessment of the iliosacral lymphatic center in dogs with anal sac gland carcinoma using indirect computed tomographic lymphography

Purpose of Study: Anal sac gland cancer is a locally aggressive cancer that has high rates of metastasis or spread through the regional lymph nodes. The use of surgery, chemotherapy and possible radiation therapy is recommended for patients with confirmed metastatic disease. Even when metastatic disease is present, reasonable survival rates have been achieved with aggressive treatment. The current gold standard for evaluation of lymph node metastasis in this disease is abdominal ultrasound of lymph nodes in the abdomen, however this technique misses lymph nodes in the pelvis that are actually closer to the primary tumor. We will evaluate the effectiveness of CT to evaluate the entire draining lymph node center in dogs with this cancer.

Participation Requirements: Dogs with an anal sac tumor that has not been surgically removed.

Initial Evaluation for Participation: Dogs must be evaluated by the UCDavis Veterinary Medical Teaching Hospital (VMTH) Soft Tissue Surgery or Medical Oncology Services and have an abdominal ultrasound performed by the UCDavis VMTH Radiology Service as part of normal pre-operative assessment for their dog’s disease.

Procedures: In addition to the standard contrast CT scans used to evaluate tumors and lymph nodes, a CT will be performed in which a small amount of contrast material will be injected subcutaneously (under the skin) very close to the primary tumor, which will help to highlight the lymphatic drainage of the region and identify the nearest lymph node to the tumor.

Benefits: The results of the CT evaluation will help determine the extent of additional disease (if present) in your dog. The CT will provide information that may improve our ability to make surgical recommendations for your dog. If disease is present in other lymph nodes that is not surgically removable for whatever reason, these procedures will still benefit your dog, as we will be able to make better post-surgical treatment recommendations, such as possible need for chemotherapy and/or radiation therapy. Costs associated with the CT scans, including the imaging and contrast material, will be covered by the study.

Owner Responsibilities: The owner is responsible for standard costs of their dog’s care (surgical removal of the primary tumor removal and any lymph nodes if so desired by the client), other pre-operative diagnostics deemed medically necessary, histopathologic analysis, hospitalization, and management of any standard surgical complications that may occur.

Contact: Call (530) 752-1393 to talk to the Specialty Coordinators or Technicians in Soft Tissue Surgery about Dr. Steffey's study.

Gastrointestinal (Colon & Rectum) Cancer: Evaluating New Diagnostic Tool

Title: Evaluation of CT pneumocolonography as a diagnostic tool in veterinary patients

Purpose of Study: The purpose of this study is to evaluate the impact of imaging findings on surgical decision-making in dogs with colonic and rectal disease of any kind (cancer or non-cancer). This part of the body can be a very difficult region examine with current imaging methods, which also do not provide optimal spatial information important if a surgical procedure is needed. In early studies, we have demonstrated the safety and efficacy of the CT pneumocolonography procedure in normal dogs, but it is important that we learn to accurately interpret the imaging findings for a wide variety of disease processes in clinical patients so that our CT diagnoses are accurate. Our goal is to compare the imaging findings obtained with CT pneumocolonography with the current standard of care of colonoscopy and colonoscopic biopsies.

Participation Requirements: In order to participate in this study, a colonoscopic exam must have been recommended for workup of your dog’s problem, and your dog must be scheduled to receive a colonoscopic exam under general anesthesia at UC Davis.

Initial Evaluation for Participation: None.

Procedures: If you agree to participate, your dog will receive a CT scan (with and without intravenous contrast material) in conjunction with carbon dioxide gas insufflated into the rectal lumen. Following CT pneumocolonography, your dog will receive the scheduled colonoscopy, which is the current standard of care for assessment of these masses, and if clinically indicated for the care of your dog, biopsies will be obtained.

Benefits: In return for participation in this study, your dog will receive a free CT scan (an approximately $800 value to you), which may directly benefit your dog, as it can provide important information for treatment recommendations that other types of imaging cannot. CT evaluation of local lymph nodes is an additional benefit as CT has been demonstrated to be helpful in the evaluation of regional lymph nodes for metastatic disease in other types of cancer in other locations.

Owner Responsibilities: There is no additional cost to you for your dog’s participation in the study. You are financially responsible for hospital costs associated with the standard care of your dog, including abdominal ultrasound, general anesthesia, colonoscopy, hospitalization, biopsies, and any other diagnostic tests recommended for evaluation of your dog’s disease by your attending clinician.

Contact: Call 530-752-1393 for Drs. Michele Steffey and Stanley Marks's study

Nasal cancer: Evaluating Chemoembolization as a Treatment Option

Title: Transarterial Chemoembolization of Nasal Tumors

Purpose of Study: The objective of this study is to evaluate alternative treatment options for patients with nasal tumors. Radiation therapy is still considered the gold standard of treatment for this disease, however clients who do not wish to pursue radiation therapy, or whose dog has failed radiation therapy may be eligible for participation in this study.

Participation Requirements:

  • Inclusion Criteria:
    • Confirmed diagnosis via cytology or histopathology (biopsy). Only dogs with tumors INSIDE the nose are eligible. This may have been done by another veterinarian, but results need to be made available to Dr. Steffey
    • CT scan performed by the UCDAVIS Radiology Department within 3 weeks of enrollment. If you are coming to UCDavis for workup of your dog’s nasal mass, nasal discharge, or nasal bleeding, PLEASE contact Dr. Steffey or discuss your interest in this study with your attending clinician BEFORE your CT scan is scheduled. If the correct pre-treatment CT parameters are not used, your dog cannot participate in the study.
    • CBC, Chemistry Panel and Urinalysis all within two weeks of enrollment (referring blood work is acceptable as long as it was performed at a commercial lab)
    • Clients *must* be willing to return at 1 month, 4 months, and 8 months for study rechecks, including a CT scan under brief general anesthesia. There is no charge for these rechecks, but it is imperative that the patient return for re-evaluation.
  • Exclusion Criteria
    • Dogs that have disease that invades the cribriform plate or is otherwise too extensive to treat safely with chemoembolization are not eligible for this study
    • Dogs that have pre-existing kidney disease that would exclude the use of radiographic contrast agents are not eligible

Initial Evaluation for Participation: All dogs must be examined by a VMTH oncology, internal medicine, radiation oncology service or soft tissue surgery veterinarian, and require the baseline evaluations described above at the owners expense before a dog can be considered for enrollment in the trial.

Procedures:

  • Chemoembolization procedure is a minimally invasive procedure. Chemotherapy and an embolic agent to obstruct the tumor blood supply are delivered directly to the tumor blood supply via special catheters
  • Recheck CT scans at 1 month, 4 months, and 8 months under general anesthesia

Benefits: THIS IS A PARTIALLY FUNDED STUDY. The procedure costs of this experimental procedure are covered by the study (an approximately $1500-2000 value to the client), but the individualized costs of the patient's care at the time of the treatment (anesthesia, hospitalization, medications, other individualized diagnostic tests needed to ensure the patient is safe for the procedure, etc) are the responsibility of the client. There will be no charge for the study rechecks at 1 month, 4 months, and 8 months. You will be financially responsible for the charges associated with the clinical care of your dog beyond the stipends provided.

Owner Responsibilities: The owner will be responsible for scheduling recheck appointments at 1 month, 4 months, and 8 months post-treatment and keeping those appointments as required by protocol. Owners also have the responsibility to cover the cost of the initial examination, blood work, pre-treatment CT scan, and any additional diagnostic tests and medications prescribed. Lastly, the owner will need to cover the cost of treatment of any complications experienced as a result of this procedure.

Contact: Contact the scheduling coordinators in Soft Tissue Surgery at (530) 752-1393 for Dr. Steffey's study.

Nasal cancer: Comparing Imaging Techniques and Assessing Vascular Therapies

Title: Nasal Tumors: Comparison of CT and MRI Findings in the Characterization of Canine Sinonasal Neoplasia and Assessment of Outcome with Vascular-Based Therapies (Embolization/Chemoembolization)

Purpose of Study: The purpose of this study is to prospectively evaluate dogs diagnosed with nasal tumors, including documentation of signalment, histologic diagnosis, treatment, and the results of a CT scan as compared to an MRI scan. We will also assess response to vascular-based therapies, such as embolization and chemoembolization.

Participation Requirements: Dogs with diagnosed nasal tumors

Initial Evaluation for Participation: Contact Dr. Culp for details at wculp@ucdavis.edu or (530) 752-1393.

Procedures: If a CT scan is recommended to further characterize the dog’s suspected nasal tumor, an MRI scan will be performed immediately following the CT scan. The MRI scan will be performed under the same general anesthetic event as the CT scan. Additionally, options concerning vascular-based therapies (embolization and chemoembolization) will be discussed and offered.

Benefits: The MRI scan and the anesthesia associated with the MRI scan will be paid for by the study. The MRI scan will offer another imaging modality that your clinician can use to make therapeutic recommendations. 

Owner Responsibilities: The owner will be responsible for scheduling appointments (initial and 2-month follow-up) and keeping those appointments as required by protocol. Financial assistance for some treatments will also be discussed upon consent.

Contact: Contact Dr. Culp for details at wculp@ucdavis.edu or (530) 752-1393.

Nasal cancer: Using a Combination of Therapies for Treatment

Title: Nasal tumors: Intra-arterial Chemotherapy and Radiotherapy to Treat Nasal Carcinoma

Purpose of Study: The purpose of this study is to prospectively evaluate the response of nasal cancer to a combination of therapies (chemotherapy and radiation therapy) in dogs.

Participation Requirements: Dogs diagnosed with nasal tumors

Initial Evaluation for Participation: Contact Dr. Culp for details at wculp@ucdavis.edu or (530) 752-1393.

Procedures: Dogs that are scheduled to receive radiation therapy for the treatment of nasal cancer can be enrolled in the study. Dogs will be placed into a group receiving radiation therapy alone or with chemotherapy.  Response to these treatments will be assessed with CT scans (done before and after treatment).

Benefits: The CT scans, chemotherapy administration, and part of the radiation therapy will be paid for by the study.

Owner Responsibilities: The owner will be responsible for providing follow-up information to the treating clinicians and returning the dog 4 weeks after initiation of radiation therapy for a second CT evaluation (the first is performed prior to treatment).

Contact: Contact Dr. Culp for details at wculp@ucdavis.edu or (530) 752-1393.

Primary Pulmonary Cancer: Using Lymphography to Identify Lymph Nodes

Title: Assessment of intraoperative lymphography as an aid to identification of regional lymph nodes in patients with primary lung tumors

Purpose of Study: Whether or not there is metastatic tumor in the regional lymph nodes is very important prognostic information for dogs with lung tumors, as dogs that do not have metastatic disease in their lymph nodes in general have a much longer lifespan. The aim of this study is to provide information that will allow us to better identify these lymph nodes at surgery to improve the safety of surgical dissection and minimize surgical time during removal of these lymph nodes.

Participation Requirements:

  • A diagnosis of a solitary lung tumor
  • Your decision to have a CT performed for staging and surgical planning of your dog’s disease
  • Your decision to pursue surgical removal of your dog’s lung tumor

Initial Evaluation for Participation: None.

Procedures: During surgery, surgical dyes will be injected into the lung around your dog’s tumor and uptake by the regional lymph nodes will be assessed.

Benefits: If your dog’s lung tumor is deemed safe to inject and you elect to take your dog to surgery, the study will retroactively pay for the CT scan ($800 value to the client). This benefits you as a thoracic CT is an important part of staging and surgical planning for any patient with a primary lung tumor. However if your dog’s tumor is not in a location that is safe to inject based on the initial plain CT scan, OR if you decide not to take your dog to surgery based on the initial plain CT scan (for example, because metastatic disease is found) then your dog cannot participate in the study and you must be prepared to pay for the CT.

Owner Responsibilities: There is no additional cost to you for your dog’s participation in the study. In return for your dog’s participation, the study will retroactively pay for the cost of your dog’s CT scan (and $800 value to you).  The study will not pay for the CT scan if you do not elect to have your dog’s lung tumor surgically removed.

Contact: Call (530) 752-1393 to talk to the Specialty Coordinators or Technicians in Soft Tissue Surgery  about Dr. Steffey's study.

Prostate cancer: Evaluating Embolization as a Treatment Option

Title: Evaluation of the Use of Embolization in the Treatment of Prostatic Neoplasia

Purpose of Study: The purpose of this project is to describe the procedure of prostatic artery embolization in a group of dogs with naturally-occurring prostate cancer. A secondary objective is to evaluate the effect that prostatic artery embolization has on clinical signs and the size of the tumor.

Participation Requirements: Dogs with prostate cancer

Initial Evaluation for Participation: Contact Dr. Culp for details at wculp@ucdavis.edu or (530) 752-1393.

Procedures: Dogs will undergo prostatic artery embolization. Pre-procedural ultrasound imaging and computed tomographic findings will be compared to post-procedural ultrasound imaging and computed tomographic findings. Complications associated with the procedure will be recorded and owners will receive a questionnaire to assess the clinical signs of the dog both pre- and post-procedure.

Benefits: The benefits of enrolling in this study include financial support for both pre- and post-procedure diagnostics. Additionally, funding from this grant will be applied towards the procedure. We hope that the data acquired in this study will allow us to advance the treatment of cancer in both dogs and people.

Owner Responsibilities: The owner will be responsible for scheduling appointments (initial and 1 month follow-up) and keeping those appointments as required by protocol.

Contact: Contact Dr. Culp for details at wculp@ucdavis.edu or (530) 752-1393.

Prostate, Urethra and/or Bladder Tumors: Evaluating Urodynamic Testing

Title: Prospective Evaluation of Urodynamic Testing in Dogs Undergoing Urethral Stent Placement to Relieve Malignant Urethral Obstruction

Purpose of Study: The purpose of this project is to determine the urethral and bladder pressures of dogs with cancer-induced urethral obstructions and in dogs with urethral stents.

Participation Requirements: Dogs with tumors causing obstruction of the urethra (bladder, urethra and prostate)

Initial Evaluation for Participation: Contact Dr. Culp for details at wculp@ucdavis.edu or (530) 752-1393.

Procedures: Urodynamic studies will be performed at the time of stent placement. Following the urodynamic studies, a urethral stent will be placed. At 3 weeks post-stent placement, canine continence scores will be obtained from clients regarding the dog’s voiding habits and urodynamic studies will be performed again.

Benefits: The goal of placing the stent is to improve the dog’s quality of life. All anesthetic episodes (2) will be paid for by the study. Additionally, all charges associated with the bladder and urethral pressure assessment will be paid for by the study. There are 2 major study benefits:

  1. We will be able to inform clients of the pressures in their dog’s bladder and urethra and discuss the possible implications of this; and,
  2. Financial compensation.

Owner Responsibilities: The owner will be responsible for scheduling appointments (initial and 3 weeks after stent placement) and keeping those appointments as required by protocol. Additionally, the owner will need to fill out forms related to their dog’s continence status.

Contact: Contact Dr. Culp for details at wculp@ucdavis.edu or (530) 752-1393.

Urethra/Bladder Tumors: Determining Tumor Size with Imaging

Title: Bladder/Urethra Tumors: Assessment and Comparison of Lower Urinary Tract Neoplasia Size and Location with Multiple Imaging Modalities

Purpose of Study: The purpose of this study is to prospectively evaluate dogs with bladder and urethral tumors and assess the best means for determining tumor size. The overarching goal is to improve our ability to treat these tumors with urethral stenting.

Participation Requirements: Dogs with bladder or urethral tumors

Initial Evaluation for Participation: Contact Dr. Culp for details at wculp@ucdavis.edu or (530) 752-1393.

Procedures: Dogs that are undergoing urethral stenting will undergo trans-rectal ultrasound (in addition to abdominal ultrasound) and MRI evaluation of the bladder/urethral tumor in order to determine tumor size and location.

Benefits: The MRI scan, the trans-rectal ultrasound and the anesthesia associated with these diagnostics will be paid for by the study. The MRI scan and trans-rectal ultrasound will offer additional imaging modalities that your clinician can use to make therapeutic recommendations.

Owner Responsibilities: The owner will be responsible for providing follow-up information to the treating clinicians.

Contact: Contact Dr. Culp for details at wculp@ucdavis.edu or (530) 752-1393.